Multiple Myeloma Clinical Trial

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Summary

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2

For participants in Cohorts A, B, C, D, E, F, H, I, J, and K the following inclusions will also apply:

Documented diagnosis of multiple myeloma (MM) and measurable disease
Documented disease progression during or after their last antimyeloma regimen
Achieved a response (minimal response [MR] or better) to at least 1 prior treatment regimen

Exclusion Criteria:

Plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) or clinically significant amyloidosis
Known central nervous system (CNS) involvement with myeloma
Received immunosuppressive medication within the last 14 days of initiating study treatment
Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

424

Study ID:

NCT03989414

Recruitment Status:

Active, not recruiting

Sponsor:

Celgene

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 49 Locations for this study

See Locations Near You

Local Institution - 119
Denver Colorado, 80218, United States
Local Institution - 104
Tampa Florida, 33612, United States
Local Institution - 108
Atlanta Georgia, 30322, United States
Local Institution - 112
Chicago Illinois, 60611, United States
Local Institution - 107
Chicago Illinois, 60637, United States
Local Institution - 117
Boston Massachusetts, 02114, United States
Local Institution - 101
Boston Massachusetts, 02115, United States
Local Institution - 118
Boston Massachusetts, 02215, United States
Local Institution - 113
Detroit Michigan, 48201, United States
Local Institution - 106
Rochester Minnesota, 55905, United States
Hackensack University Medical Center
Hackensack New Jersey, 07601, United States
Local Institution - 110
Winston-Salem North Carolina, 27157, United States
Local Institution - 115
Columbus Ohio, 43210, United States
Local Institution - 114
Nashville Tennessee, 37203, United States
Local Institution - 116
Houston Texas, 77030, United States
Swedish Cancer Institute
Seattle Washington, 98104, United States
Local Institution - 201
Calgary Alberta, T2N 4, Canada
Local Institution - 205
Edmonton Alberta, T6G 2, Canada
Local Institution - 204
Halifax Nova Scotia, B3H 1, Canada
Local Institution - 203
Toronto Ontario, M5G 2, Canada
Local Institution - 202
Montreal Quebec, H1T 2, Canada
Local Institution - 802
Brno , 625 0, Czechia
Local Institution - 801
Ostrava-Poruba , 708 5, Czechia
Local Institution - 803
Praha 2 , 128 0, Czechia
Local Institution - 902
Odense , 5000, Denmark
Local Institution - 903
Vejle , 7100, Denmark
Local Institution - 703
Lille cedex , 59037, France
Local Institution - 705
Marseille cedex , 13273, France
Local Institution - 704
Nantes Cedex 01 , 44093, France
Local Institution - 701
Toulouse Cedex 9 , 31059, France
Local Institution - 702
Tours cedex , 37044, France
Local Institution - 604
Freiburg , 79106, Germany
Local Institution - 605
Hamburg , 20246, Germany
Local Institution - 601
Heidelberg , 69120, Germany
Local Institution - 602
Munchen , 81675, Germany
Local Institution - 603
Wuerzburg , 97080, Germany
Local Institution - 301
Athens , 115 2, Greece
Local Institution - 404
Brescia , 25123, Italy
Local Institution - 401
Milan , 20133, Italy
Local Institution - 403
Reggio Emilia , 42100, Italy
Local Institution - 402
Torino , 10126, Italy
Local Institution - 504
Badalona , 08916, Spain
Local Institution - 508
Madrid , 28022, Spain
Local Institution - 501
Madrid , 28041, Spain
Local Institution - 506
Malaga , 29010, Spain
Local Institution - 505
Pamplona , 31008, Spain
Local Institution - 502
Salamanca , 37007, Spain
Local Institution - 503
Santander , 39008, Spain
Local Institution - 507
Valencia , 46026, Spain

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

424

Study ID:

NCT03989414

Recruitment Status:

Active, not recruiting

Sponsor:


Celgene

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.